CytoMed Therapeutics Limited Ordinary Shares GDTC · Stock Open CytoMed Therapeutics Limited Ordinary Shares in new tab
CytoMed Therapeutics Limited Ordinary Shares Analysis (GDTC)
Is CytoMed Therapeutics Limited Ordinary Shares a good investment? CytoMed Therapeutics Limited Ordinary Shares (GDTC) is currently trading at 0.9100 USD.
Earnings Schedule: CytoMed Therapeutics Limited Ordinary Shares is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.15.
Investor FAQ
Does CytoMed Therapeutics Limited Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is CytoMed Therapeutics Limited Ordinary Shares?
CytoMed Therapeutics Limited Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -0.27.
Company Profile
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Community Discussion